KRYS
Krystal Biotech, Inc.
Stock
$322.28−3.03 (−0.93%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $272M | $201M | $123M | −$89M | −$101M | −$48M | −$26M | −$19M | −$9.4M | −$3.9M | −$1.3M |
| Capital expenditures | $15M | $12M | $4.2M | $12M | $53M | $68M | $15M | $6.4M | $2.2M | $210K | $15K |
| Free cash flow | $258M | $189M | $119M | −$101M | −$154M | −$116M | −$41M | −$25M | −$12M | −$4.1M | −$1.3M |
| Stock-based compensation | $55M | $55M | $49M | $40M | $33M | $15M | $3.3M | $1.2M | $792K | $246K | $33K |
| Free cash flow margin | 58.5% | 48.5% | 41.0% | −198.4% | — | — | — | — | — | — | — |